Home / Asia-Pacific / Hong Kong / Life Sciences & Healthcare
Life sciences picture - microscope

Life Sciences & Healthcare

As a participant in the lifesciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market.

With more than 480 lawyers, patent attorneys, scientists and academics across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector.

We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

"The team is described by one grateful client as being "very responsive and reliable regarding their legal advice to us."

Chambers and Partners

A market commentator emphasises the team's "wide legal service network and dedication," adding: "The firm is super good in handling multi-jurisdictional legal issues."

Chambers and Partners

Feed

15/09/2022
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? The primary source of le­gis­la­tion in Hong Kong that gov­erns both ad­vert­ise­ments of medi­cines and med­ic­al devices is...
07/06/2022
Ad­verse ef­fects of drugs and vac­cines in Hong Kong
1. Drug ad­verse ef­fects: kinds of re­spons­ib­il­ity 1.1 Which are the main kinds of re­spons­ib­il­ity (con­trac­tu­al, in tort, crim­in­al) of the fol­low­ing sub­jects with re­spect to ad­verse drugs re­ac­tions? There...
Comparable
07/06/2022
Trade secret laws and reg­u­la­tions in Hong Kong
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
Comparable
01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
26/11/2021
COV­ID-19 vac­cin­a­tion and test­ing in Hong Kong - em­ploy­ment law per­spect­ive
Vac­cin­a­tion 1. What op­tions does the em­ploy­er have to en­cour­age em­ploy­ees to be vac­cin­ated? Can the em­ploy­er provide a fin­an­cial in­cent­ive to em­ploy­ees?  There are no gen­er­al re­stric­tions on em­ploy­ers...
Comparable
24/11/2021
On the Pulse
Wel­come to CMS ‘On the Pulse’ video/pod­cast series for all Life Sci­ences & Health­care pro­fes­sion­als – leg­al, com­pli­ance, reg­u­lat­ory
27/10/2021
Epis­ode #1 - Nav­ig­at­ing the data pro­tec­tion land­scape in Asia, in­clud­ing...
Nick Beck­ett (Beijing/Hong Kong) chats with Jonath­an Chu (Hong Kong) and Sheena Jac­ob (Singa­pore) on data pro­tec­tion and in par­tic­u­lar:Does Asia need a GDPR equi­val­ent? The new China PIPL - should com­pan­ies be con­cerned? Cross-bor­der trans­fers of per­son­al data in Asia - cut­ting through the thick­et So you have a breach in Asia - how to man­age a data breach in this part of the world Cy­ber­se­cur­ity laws and reg­u­la­tion of crit­ic­al sec­tors - the new na­tion­al se­cur­ity fron­ti­er
26/10/2021
CMS Tech In­nov­a­tion Asia
Wel­come to CMS’s ‘Tech In­nov­a­tion Asia’ video/pod­cast series for pro­fes­sion­als deal­ing with leg­al, com­pli­ance, IP and reg­u­lat­ory is­sues in the Asia-Pa­cific re­gion.
29/11/2021
Glob­al Life Sci­ences & Health­care Fest­iv­al 2021 - Vir­tu­al
Join us for this year's Glob­al Life Sci­ences & Health­care Fest­iv­al 2021 - Vir­tu­al from 29 Novem­ber to 2 Decem­ber.  Day 1: Ar­ti­fi­cial In­tel­li­gence in Life Sci­ences & Health­care: New busi­ness mod­els in...
17/09/2021
Vac­cine com­pens­a­tion re­gimes in Hong Kong
1. Are COV­ID-19 vac­cin­a­tions ob­lig­at­ory in your jur­is­dic­tion? Are you ex­pect­ing any le­gis­lat­ive changes to en­able man­dat­ory vac­cines for all or cer­tain people (e.g. health­care pro­fes­sion­als, pub­lic ser­vants...
Comparable
13/07/2021
Open Secrets? Guard­ing value in the in­tan­gible eco­nomy
Across mul­tiple in­dus­tries, busi­nesses are de­riv­ing an ever great­er pro­por­tion of their value from as­sets pro­tec­ted not by pat­ent or copy­right – but by secrecy. And from cus­tom­er data to soft­ware al­gorithms...
02/10/2020
BRI - View from APAC
The Asia-Pa­cific re­gion (APAC) has seen ex­tens­ive Belt and Road (BRI) in­vest­ment already, and prom­ises much more.But our sur­vey of BRI par­ti­cipants in APAC re­veals un­ex­pec­ted levels of am­bi­val­ence about some as­pects of BRI pro­jects.Can these po­ten­tial dif­fi­culties be tackled in a way that will ad­dress con­cerns about is­sues such as trans­par­ency and sus­tain­ab­il­ity, and en­cour­age the great­er in­volve­ment of in­ter­na­tion­al busi­nesses that China hopes to see? And how are the un­pre­ced­en­ted prob­lems of 2020, in­clud­ing the glob­al pan­dem­ic and trade dis­putes, af­fect­ing the pro­spects of BRI?Our APAC re­port looks at is­sues in­clud­ing:Dif­fi­culties in BRI pro­jects ex­per­i­enced by APAC par­ti­cipants, and the po­ten­tial for resolv­ing these.The ef­fects of Cov­id-19 on BRI.Mit­ig­at­ing BRI risk and man­aging dis­putes.Po­ten­tial trends in the fin­an­cing of BRI pro­jects.The sec­tors at­tract­ing the most in­terest among BRI par­ti­cipants.The im­pact of BRI 2.0.